Cooperative Cyclic Hormone Replacement (ccHRT)

Cooperative Cyclic Hormone Replacement (ccHRT) is hormone replacement timed to support a woman's own cycle. It works with her cycle instead of imposing a set external schedule on it. Its defining feature is individual tailoring to each woman.

Cycle charting and repeated hormone blood tests guide it. It uses hormones identical to those the body produces (body-identical, or isomolecular). It does not use synthetic hormones.

Standard hormone replacement usually follows a set schedule. It is not matched to the signs of a woman's own cycle. Sequential and cyclic regimens do exist in mainstream care. ccHRT goes further. It times each dose to the woman's cycle as it unfolds, based on what the cycle itself shows.¹

The Cycle as the Guide

ccHRT treats the cycle as a source of useful information, not an obstacle to manage. Charting shows where a woman is in her cycle. Hormone tests confirm her levels. Most of these tests fall in the luteal phase, the phase of the cycle after ovulation.

Those tests guide whether and how to use it. Without that data, the clinician is what restorative medicine describes as flying blind.

Two cycle-timed protocols put this approach into practice: cooperative estrogen replacement and cooperative progesterone replacement. Dr. Thomas W. Hilgers developed and defined both within NaProTechnology.¹² ccHRT is the umbrella concept that unites them.

Body-Identical Hormones: The Material Distinction

ccHRT uses these body-identical hormones, not synthetic progestins. Progesterone is the hormone the body produces after ovulation. Synthetic progestins are chemically altered molecules.

Progestins bind the same receptors but act differently in tissue. For this reason, the two are not interchangeable. Research papers often create confusion when they label progestins as "progesterone."

One large systematic review and meta-analysis pooled data on 86,881 postmenopausal women. Each hormone was paired with estrogen. Body-identical progesterone was associated with a lower breast cancer risk than synthetic progestins.³ This finding makes the preference a real clinical choice, not a marketing one.

Scope: Cycling Women, Pregnancy, and the Menopausal Transition

ccHRT applies in three distinct settings.

In women of reproductive age who still have cycles, the goal is to support a deficient luteal phase. That support follows the cycle's own rhythm. NaProTechnology protocols for these women measure each woman's own luteal hormone levels. That measurement decides when, and whether, ccHRT fits.²

In pregnancy, progesterone support of this type has a documented role. It helps maintain the hormone levels needed for implantation and for development of the placenta (placentation). One review examined 1,310 pregnancies supported this way within NaProTechnology. It covered both clinical use and the evidence on fetal safety.⁴

Pregnancy is the most demanding application. Here the stakes of steady, well-timed support are highest. The margin for error is smallest. Recurrent pregnancy loss is the most difficult form of this challenge.

It requires precise hormone support. It also involves autoimmune and other systemic factors that research has not yet fully mapped.

Near menopause, ccHRT applies the same principle. It is tailored to the woman and guided by testing. Body-identical hormones are preferred throughout.

Why the Distinction from Conventional HRT Matters

Standard hormone regimens are designed for the average woman. ccHRT is designed for one woman in one cycle. Follicle maturation studies and sonographic ovulation classification are tools designed to close that gap.

They confirm more than whether ovulation occurred. They show the quality of that ovulation and the response of the luteal phase.

Conditions such as LUF syndrome and partial rupture syndrome can make a chart appear normal while they conceal real defects in egg release. A plan that ignores those defects rests on incomplete information. ccHRT closes that gap. It requires an understanding of the cycle before the cycle receives support.

The restorative principle is to work with the cycle, describe it precisely, and support what is deficient. The suppressive model, in contrast, overrides the whole cycle. The static-dose model replaces hormones on a set schedule, without regard to the woman's own physiology.

For more on how RRM evaluates ovarian reserve, FSH changes and ovulation, see the linked terms.